Literature DB >> 26215941

Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence.

Cécile Le Péchoux1, Ariane Dunant2, Corinne Faivre-Finn3, Pascal-Alexandre Thomas4, Nicolas Pourel5, Delphine Lerouge6, John Edwards7, Paul Van Schil8, Ramon Rami-Porta9, Eric Dansin10, Ursula Nestle11, Elie Fadel12, Gerard Zalcman13.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26215941     DOI： 10.1200/JCO.2015.62.1458

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out!

Authors:  Lawek Berzenji; Paul Beckers; Paul E Van Schil
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

2.  Multimodality therapy in subclassified stage IIIA-N2 non-small cell lung cancer patients according to the Robinson classification: heterogeneity and management.

Authors:  Hans-Stefan Hofmann; Jan Braess; Susanne Leipelt; Michael Allgäuer; Monika Klinkhammer-Schalke; Tamas Szoeke; Christian Grosser; Michael Pfeifer; Michael Ried
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers.

Authors:  Yanyan Lou; Bhagirathbhai Dholaria; Aixa Soyano; David Hodge; Jordan Cochuyt; Rami Manochakian; Stephen J Ko; Mathew Thomas; Margaret M Johnson; Neal M Patel; Robert C Miller; Alex A Adjei; Sikander Ailawadhi
Journal:  Cancer Med       Date:  2018-09-02       Impact factor: 4.452

4.  PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study.

Authors:  Xiaoling Shang; Zhenxiang Li; Jiamao Lin; Haiyong Wang; Zhehai Wang
Journal:  Cancer Manag Res       Date:  2018-09-17       Impact factor: 3.989

5.  Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study.

Authors:  Wei Wei; Jiao Zhou; Qun Zhang; De-Hua Liao; Qiao-Dan Liu; Bei-Long Zhong; Zi-Bin Liang; Yong-Chang Zhang; Rong Jiang; Gui-Yun Liu; Chen-Yang Xu; Huai- Li Zhou; Su-Yu Zhu; Nong Yang; Wen Jiang; Zhi-Gang Liu
Journal:  Cancer Med       Date:  2020-02-26       Impact factor: 4.452

6.  Postoperative chemoradiotherapy is superior to postoperative chemotherapy alone in squamous cell lung cancer patients with limited N2 lymph node metastasis.

Authors:  Liyu Su; Mingqiu Chen; Huiyan Su; Yaqing Dai; Shaoxing Chen; Jiancheng Li
Journal:  BMC Cancer       Date:  2019-10-30       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.